跳至主要内容
临床试验/ACTRN12610000055000
ACTRN12610000055000进行中(未招募)未知

Response Post Tyrosine Kinase Inhibitor: Assesment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML).

Australasian Leukaemia and Lymphoma Group (ALLG)0 个研究点目标入组 1,000 人开始时间: 2010年1月19日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
o limit 至 o limit(—)
性别
All

入选标准

  • Patients of any age
  • Currently recieving Tyrosine Kinase Inhibitor(TKI)
  • Patients with Philadelphia Positive or Breakpoint Cluster Region (BCR) V-abl Abelson murine leukaemia viral oncogene homolog1 (ABL) confirmed CML.
  • Patients in any phase of CML including those with relapsed CML following allogeneic stem cell transplantation
  • Patients who can provide written informed consent. Minors must have parental/legal guardian consent and assent where required

排除标准

  • If in the investigator's opinion the patient is unlikely candidate for follow-up information due to unavailability.
  • Previous enrolment to the same registry.

研究者

发起方
Australasian Leukaemia and Lymphoma Group (ALLG)

相似试验